SCHEMBL15020757

SCHEMBL15020757

CCOCc1nn2c(-c3cccc(F)c3)cc(N3CCCC3CO)nc2c1-c1ccc(OC)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FPR2 P25090 1/20 0.39
▸ SCN9A Q15858 1/20 0.39
▸ MAPT P10636 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ PLAT P00750 1/20 0.35
▸ SPHK2 Q9NRA0 1/20 0.34
▸ SRC P12931 2/20 0.34
▸ TRPV1 Q8NER1 1/20 0.34
▸ ADORA3 P0DMS8 1/20 0.34
▸ ADORA2A P29274 1/20 0.34
▸ ADORA1 P30542 1/20 0.34
▸ KDM4E B2RXH2 4/20 0.34
▸ ALDH1A1 P00352 3/20 0.34
▸ ITGB2 P05107 1/20 0.34
▸ ICAM1 P05362 1/20 0.34
▸ ITGAL P20701 1/20 0.34
▸ HTT P42858 1/20 0.34
▸ CDK1 P06493 1/20 0.34
▸ LMNA P02545 1/20 0.33
▸ HCRTR1 O43613 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15020805 0.93 CDK1 (0.38) FPR2SCN9AMAPTMAPK1PLAT
SCHEMBL15021293 0.93 FPR2 (0.37) FPR2SCN9AMAPTADORA3ADORA2A
SCHEMBL15021381 0.93 FPR2 (0.44) FPR2SCN9AMAPTMAPK1PLAT
SCHEMBL15020926 0.92 FPR2 (0.36) FPR2SCN9ASPHK2ALDH1A1ITGB2
SCHEMBL15020885 0.92 HCRTR1 (0.37) FPR2SCN9AMAPTMAPK1PLAT
SCHEMBL15020883 0.92 HCRTR1 (0.37) FPR2SCN9AMAPTMAPK1PLAT
SCHEMBL15020534 0.91 SPHK2 (0.41) FPR2SCN9AMAPTMAPK1PLAT
SCHEMBL15020880 0.89 CDK1 (0.37) FPR2SCN9AMAPTMAPK1SPHK2
SCHEMBL15021467 0.88 MAPT (0.48) FPR2SCN9AMAPTMAPK1SRC
SCHEMBL15020889 0.87 KDM4E (0.36) FPR2SCN9AMAPTKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 — — US claimed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 — — US claimed
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 — — US disclosed
EP-2617723-A2 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR Amorepacific Corporation (KR) 2013-07-24 — — EP disclosed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR CNR1, CNR2, GPR18 FPR2 2908/4885SCN9A 615/4885MAPT 2617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback